LeadershipAdvocacy & Gov't AffairsHistoryCareers at Joslin
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare ProfessionalsJoslin Clinical Guidelines
Adult ClinicYoung Adult Transition CarePediatricsEye CareWeight Management ProgramsDO ITMental Health & CounselingReferring PhysiciansBillingAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare ProfessionalsClinical Guidelines
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside Joslin
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCause MarketingCommercialization and VenturesHealthcare Professionals
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

News Release

Study Identifies Cells that Give Rise to Brown Fat

In a step toward novel weight-loss therapies, Joslin scientists identify cells in mice that can be triggered to transform into energy-burning brown fat

BOSTON – December 20, 2010 – In some adults, the white fat cells that we all stockpile so readily are supplemented by a very different form of fat—brown fat cells, which can offer the neat trick of burning energy rather than storing it. Researchers at Joslin Diabetes Center, which last year led the way in demonstrating an active role for brown fat in adults, now have identified progenitor cells in mouse white fat tissue and skeletal muscle that can be transformed into brown fat cells.

“This finding opens up a whole new avenue for researchers working to induce endogenous progenitor cells to differentiate into mature brown fat cells,” says Yu-Hua Tseng, Ph.D., Joslin Investigator and senior author on a paper describing the work published online in the journal PNAS in the week of December 20, 2010.

“It’s particularly exciting because we found that some of these cells are located in subcutaneous white fat, which could be a very accessible source for them,” says Tseng, who is also Assistant Professor of Medicine at Harvard Medical School.

Scientists in her lab carried out in vitro tests of cells in mice found in different fat tissues and skeletal muscle that were marked with a protein called Sca1. When these cells were exposed to a protein called BMP-7, a key factor in brown fat development previously identified by the Tseng lab, many displayed markers of brown fat cells.

Moreover, the investigators showed that conversion rates climbed for progenitor cells in subcutaneous white fat when they were exposed not just to BMP-7 but to the diabetes drug rosiglitazone, which other studies had previously demonstrated aids in brown fat differentiation.

The work also showed that the Sca1-positive progenitor cells identified in various mouse fat depots and muscle tissue differed in their molecular signatures and in how amenable they were to undergoing this transformation.

Additionally, the researchers exposed the isolated precursor cells to BMP-7 in vitro and re-injected them into the mice, where the cells survived and transfigured into mature brown fat. This suggested that cell-based brown fat therapies eventually may be possible if drugs don’t pan out.

“We are still looking for the human equivalent of the Sca1 marker for these progenitor cells,” notes Tseng. “But we also tested cells isolated from different kinds of human fat, and we found that BMP-7 can induce precursors derived from human white fat to show a marker of differentiated brown fat cells.”

“Of course, diet and exercise are still the best approaches for losing weight in the general population, but for people who are genetically predisposed to obesity, or those who already develop detrimental metabolic disorders due to excess body weight, there is an urgent need to develop new interventions for effective and safe weight reduction,” she says. “These results appear to take a significant step toward using brown fat cells in such therapies.”

The paper’s lead author is Tim J. Schulz, a postdoctoral scientist in the Tseng lab. Other contributors include Tian Lian Huang, Thien T. Tran, Hongbin Zhang, Kristy L. Townsend, Jennifer L. Shadrach, Massimiliano Cerletti, Lindsay E. McDougall and Amy J. Wagers of Joslin; Nino Giorgadze, Tamara Tchkonia and James L. Kirklandof the Mayo Clinic in Rochester, Minn.; and Denis Schrier and Dean Falb of Stryker Biotech.

Lead funders for the research were the National Institutes of Health, Harvard Catalyst, the Harvard Stem Cell Institute, the German Research Foundation and the Eli Lilly Research Foundation.